A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
A pharmacokinetic study in healthy volunteers to determine the relative bioavailability of
 three formulations of celecoxib to the approved formulation.
Pharmacokinetics
Inclusion Criteria:

 -  Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive
 (Healthy is defined as no clinically relevant abnormalities identified by a detailed
 medical history, full physical examination, including blood pressure (BP) and pulse
 rate measurement, 12-lead ECG and clinical laboratory tests);

 -  Body Mass Index (BMI) of approximately 18 to 32 kg/m2; and a total body weight >50 kg
 (110 lbs). A BMI lower limit of 17.5kg/m2 may be rounded up to 18.0 kg/m2, a BMI upper
 limit of 32.5 kg/m2 may be rounded down to 32.0 kg/m2 and will be acceptable for
 inclusion;

 -  Evidence of a personally signed and dated informed consent document indicating that
 the subject (or a legally acceptable representative) has been informed of all
 pertinent aspects of the trial;

 -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
 laboratory tests, and other trial procedures.

 Exclusion Criteria:

 -  Evidence or history of clinically significant hematological, renal, endocrine,
 pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
 allergic disease (including drug allergies, but excluding untreated, asymptomatic,
 seasonal allergies at time of dosing);

 -  Any condition possibly affecting drug absorption (eg, gastrectomy).

 -  A positive urine drug screen;

 -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer
 or 1.5 ounces (45 mL) of hard liquor), within 6 months of screening;

 -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 5
 cigarettes per day;

 -  Treatment with an investigational drug within 30 days or 5 half-lives preceding the
 first dose of study medication;

 -  12-lead ECG demonstrating QTc >450 msec at Screening. If QTc exceeds 450 msec, the ECG
 should be repeated two more times and the average of the three QTc values should be
 used to determine the subject's eligibility;

 -  Pregnant or nursing females; females of childbearing potential who are unwilling or
 unable to use an acceptable method of non-hormonal contraception, as outlined in this
 protocol, from at least 14 days prior to the first dose of study medication until
 completion of follow-up procedures;

 -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or
 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal
 supplements and hormonal methods of contraception (including oral and transdermal
 contraceptives, injectable progesterone, progestin subdermal implants,
 progesterone-releasing IUDs, postcoital contraceptive methods) and hormone replacement
 therapy must be discontinued 28 days prior to the first dose of study medication.
 Depo-Provera® must be discontinued at least 6 months prior to the first dose of study
 medication. As an exception, acetaminophen/paracetamol may be used at doses of less
 than or equal to 1 g/day. Limited use of non-prescription medications that are not
 believed to affect subject safety or the overall results of the study may be permitted
 on a case-by-case basis following approval by the sponsor;

 -  Use of grapefruit containing products within at least 7 days prior to the
 administration of study medication;

 -  Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing;

 -  History of sensitivity to heparin or heparin-induced thrombocytopenia;

 -  Unwilling or unable to comply with the Lifestyle guidelines described in this
 protocol;

 -  Subjects who have pre-existing asthma, a known hypersensitivity to celecoxib, or have
 experienced asthma, urticaria or allergic-type reactions after taking sulfonamides,
 aspirin, selective COX-2 inhibitors, or other non-steroidal anti-inflammatory drugs
 (NSAIDs);

 -  Subjects with a prior history of ulcer disease or gastrointestinal bleeding;

 -  Other severe acute or chronic medical or psychiatric condition or laboratory
 abnormality that may increase the risk associated with study participation or
 investigational product administration or may interfere with the interpretation of
 study results and, in the judgment of the investigator, would make the subject
 inappropriate for entry into this study.